Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

• Patients with clinical diagnosis of pure impetigo, impetigo contagiosa, or uncomplicated blistering impetigo
• Patients 2 years of age or older, and in general good health
• Patients with no less than two lesions and no more than seven lesions, area 0.5x0.5cm.
• No known medical conditions that, in the Investigator's opinion could interfere with study participation
• Patient / Patient's guardian (in the case of children) willing and able to comply with all requirement of the protocol
• Patient / Patient's guardian willing and able to give written informed consent prior to participation in the study

Exclusion Criteria:

• Presence of skin diseases at or near the investigational area
• Immunosuppressed state or other serious systemic disease
• Signs and/or symptoms of systemic infection
• Presence of skin infection/disorder not amenable to topical antibacterial treatment only
• Presence of secondarily-infected animal/human bite
• Presence of secondarily infected burn wound
• Topical or systemic use of medicinal or other products before or during the study (oral or topical antibiotics, oral or topical corticosteroids and immuno modulators); or other drugs, which in the Investigators opinion could confound the evaluation of the effect of the study drugs
• Known or suspected hypersensitivity to Minocycline or any of the excipients in the study medication
• Participation in any other investigational drug study or use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to randomization
• Patients previously enrolled/randomized in this study
• Use of another investigational drug within 30 days prior to entry into this study.
• Pregnant or lactating women.